Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA

by NASDAQ Market News March 16, 2020

NASDAQ Market News
Click here to email author

Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients

Grokker Extends Free Access to Companies to Support Workforce Wellbeing During COVID-19 Outbreak

Ads